<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04095806</url>
  </required_header>
  <id_info>
    <org_study_id>ZAHREC/02/July/2019/47</org_study_id>
    <nct_id>NCT04095806</nct_id>
  </id_info>
  <brief_title>Zanzibar Stroke Study: Narrowing the Gaps in Hypertension Care, and Improving Stroke Outcomes (ZanStroke)</brief_title>
  <acronym>ZanStroke</acronym>
  <official_title>Zanzibar Stroke Study. Using a Prospective Register-based Study, Qualitative Research, and Economic Analysis to Support Evidence Synthesis for Health Policy and System Change in Zanzibar, Tanzania.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jutta Mari Adelin Jorgensen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Newcastle University, UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vervig (IoM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mnazi Mmoja National Referral Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      A previous study in Zanzibar (which Jutta Adelin Jorgensen, PI of ZanStroke, led) showed a&#xD;
      high prevalence of hypertension among adults at 33%, in fact higher than average in&#xD;
      Sub-Saharan Africa (SSA), and poor performance of the health systems with nearly 90% of&#xD;
      people with hypertension not achieving adequate blood pressure control. Uncontrolled&#xD;
      hypertension (HTN) and stroke have already become among the commonest causes of admission to&#xD;
      and death at hospital in Zanzibar. At the same time, there is little or no data available to&#xD;
      quantify the stroke burden on types, treatment and outcomes, cost of stroke care, nor a&#xD;
      comprehensive understanding of the causes of poor hypertension control in the population.The&#xD;
      Tanzanian Stroke Incidence study (which Richard Walker from Newcastle University led) showed&#xD;
      some of the highest stroke incidence rates in the world. However, there are many unanswered&#xD;
      questions, and the Zanzibar Stroke Study will be a unique opportunity to look at all stroke&#xD;
      admissions from a large island population.&#xD;
&#xD;
      Zanzibar Stroke Study:&#xD;
&#xD;
      The hypotheses investigated are&#xD;
&#xD;
      1a. Current challenges in stroke care cannot exclusively be explained by limited structural&#xD;
      resources, and care delivering processes play an essential role.&#xD;
&#xD;
        1. b. Current organization and quality of care for stroke including rehabilitation could&#xD;
           benefit from being aligned with best practices for low resource settings.&#xD;
&#xD;
        2. a. Stroke types, causes, and prognosis are dominated by a higher proportion of&#xD;
           hemorrhagic strokes, associated to poorly controlled hypertension, higher 30-day&#xD;
           mortality, and worse prognosis in terms of disability and mortality at 12 months than&#xD;
           seen in high income settings.&#xD;
&#xD;
      2b Long term stroke outcome is not only depending on stroke severity but also on&#xD;
      sociodemographic/economic factors with worse prognosis for the poorest part of the&#xD;
      population.&#xD;
&#xD;
      3a. There is a significant first stage delay due to local perceptions and beliefs around&#xD;
      stroke which prohibits biomedical treatment in the prognostically important acute phase of&#xD;
      stroke 3b. There are untapped resources in the community that could be leveraged to increase&#xD;
      adherence to medical treatment to control BP to prevent stroke and re-stroke, as well as&#xD;
      making rehabilitation accessible 4a. Introducing a hypertension care package at lowest&#xD;
      primary care level for people at high cardiovascular disease (CVD) risk to prevent stroke and&#xD;
      re-stroke is cost-effective, affordable, and possible.&#xD;
&#xD;
      4b. With no intervention, the cost of stroke care at hospital level will in 10 years exceed&#xD;
      the cost of all reproductive and child health (RCH) services.&#xD;
&#xD;
      ZanStroke is an observational, prospective study of stroke admissions to hospitals in&#xD;
      Zanzibar (Unguja) enrolling all patients with a recent stroke (&lt; 30 days) over a period of&#xD;
      one year to investigate the burden of stroke disease, risk factors and outcome up till 12&#xD;
      months post-stroke. This will be done through establishing a stroke patient register.&#xD;
&#xD;
      Participant data will include sociodemographic and -economic information, vascular risk&#xD;
      factors and previous medical history, routine head-CT, routine biochemical results and other&#xD;
      investigations, as well as early and long-term outcomes (deaths, disability,&#xD;
      independence/functionality, quality of life, cognition, medicine adherence, rehabilitation&#xD;
      therapy, re-stroke).&#xD;
&#xD;
      Approximately 80% of stroke patients in Unguja, Zanzibar who seek hospital care are admitted&#xD;
      to the main hospital and the nearby private hospital, and these will undergo CT head scan,&#xD;
      but this will not be possible in all of the other six hospitals. We will take blood samples&#xD;
      and store serum and deoxyribonucleic acid (DNA) for potential future analysis from the main&#xD;
      hospital and the nearby private hospital only.&#xD;
&#xD;
      In addition to the clinical epidemiological research, qualitative and health economic&#xD;
      evaluation research will be undertaken to understand stroke patients and caretakers life&#xD;
      worlds and perspectives, health care providers skills and practices, organization and&#xD;
      processes of stroke care at hospital level, and to define a set of most cost-effective&#xD;
      interventions to prevent and treat stroke in the particular Zanzibar context.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current and future benefits and impacts:&#xD;
&#xD;
      With the demographic transition and population ageing in SSA rates of stroke are set to&#xD;
      continue to increase rapidly as part of the double burden of disease (still a major burden of&#xD;
      infectious diseases, as well as an unfinished agenda of maternal and newborn health).&#xD;
&#xD;
      Previous studies have already established a global high level of hypertension in the adult&#xD;
      population in Zanzibar, and low performance of the health system for managing this.&#xD;
&#xD;
      It is important to identify the peculiar genomic, gene-environmental and environmental risk&#xD;
      and protective factors for stroke occurrence, pattern, type, outcome, and current incidence&#xD;
      velocity in SSA in order to inform preventive measures especially effective and&#xD;
      cost-effective control of raised blood pressure/hypertension; the best model for the&#xD;
      provision of inpatient care and rehabilitation in a resource poor environment with lack of&#xD;
      access to dedicated stroke units and limited multidisciplinary team input; and to include the&#xD;
      particular East Africa population in existing or future international stroke collaborations&#xD;
      to ensure that genetic variations relevant to the population there are represented.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 3, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 3, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>30 day mortality</measure>
    <time_frame>30 days post stroke; data collected over 12 months</time_frame>
    <description>Mortality rate of stroke patients 30 days post stroke</description>
  </primary_outcome>
  <primary_outcome>
    <measure>90 days mortality</measure>
    <time_frame>90 days post stroke; data collected over 12 months</time_frame>
    <description>Mortality rate of stroke patients 90 days post stroke</description>
  </primary_outcome>
  <primary_outcome>
    <measure>12 months mortality</measure>
    <time_frame>12 months post stroke; data collected over 12 months</time_frame>
    <description>Mortality rate of stroke patients 12 months post stroke</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disability at 30 days</measure>
    <time_frame>30 days post stroke; data collected over 12 months</time_frame>
    <description>disability of stroke patients as measured using the modified Ranking Scale (mRS) at 30 days post stroke.&#xD;
The modified Rankin Scale (mRS) assesses disability in patients who have suffered a stroke and is compared over time to check for recovery and degree of continued disability. A score of 0 is no disability, 5 is disability requiring constant care for all needs; 6 is death.&#xD;
The mRS has been used in clinical research for over 30 years and is a common standard for assessing functional outcomes in patients with stroke.&#xD;
Multiple studies have shown that the mRS correlates with physiological indicators such as stroke type, lesion size and neurological impairment as assessed by other stroke evaluation scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability at 12 months</measure>
    <time_frame>12 months post stroke; data collected over 12 months</time_frame>
    <description>disability of stroke patients as measured using modified Rankin Scale (mRS) at 12 months post stroke. The modified Rankin Scale (mRS) assesses disability in patients who have suffered a stroke and is compared over time to check for recovery and degree of continued disability. A score of 0 is no disability, 5 is disability requiring constant care for all needs; 6 is death.&#xD;
The mRS has been used in clinical research for over 30 years and is a common standard for assessing functional outcomes in patients with stroke.&#xD;
Multiple studies have shown that the mRS correlates with physiological indicators such as stroke type, lesion size and neurological impairment as assessed by other stroke evaluation scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive impairment at 3 and 12 months</measure>
    <time_frame>3 and 12 months post stroke; data collected over 12 months</time_frame>
    <description>Cognitive impairment of stroke patients 3 and 12 months post stroke using the Identification and Intervention for Dementia in Elderly Africans (IDEA) cognitive screening tool .&#xD;
The first 4 items involve being able to name a bridge from a description of its use, knowing the day of the week, knowing the name of the village chief/ town mayor/ city governor and naming as many animals as possible in one minute (score 2 for â‰¥ 8 animals, score 1 for 4-7 animals, score 0 for 0-3 animals). Item 5 is a 10-word recall test (score 1 point for each word up to a maximum of 5 points). The sixth item is designed to measure praxis and involves a matchstick design test with scores ranging from 0 (no matchsticks placed correctly), to 3 (all four matchsticks placed correctly).&#xD;
The maximum possible score is 15 and the minimum 0, with a higher score indicating better cognitive function. 7/8 is used as a cut-off for dementia, and 10/11 a cut-off for cognitive impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related Quality of Life at 3 and 12 months</measure>
    <time_frame>3 and 12 months post stroke; data collected over 12 months</time_frame>
    <description>Quality of life among stroke patients 3 and 12 months post stroke using the 5-level EQ-5D instrument.&#xD;
The EQ-5D is a standardized non-disease specific instrument to describe and value health-related quality of life and consist of a descriptive system and a visual analogue scale (VAS).&#xD;
The descriptive system comprises of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels. The patient indicates his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.&#xD;
The EQ VAS records the patient's self-rated health on a vertical visual analogue scale ( 0-10), where the endpoints are labelled 'The best health you can imagine' (0) and 'The worst health you can imagine' (10).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medicine Adherence at 3 and 12 months</measure>
    <time_frame>3 and 12 months post stroke; data collected over 12 months</time_frame>
    <description>Medicine adherence among stroke patients 3 and 12 months post stroke using the Medicine Adherence Questionnaire (MAQ).&#xD;
MAQ is a standardized instrument to assess intentional and un-intentional non-adherence and consist of four questions with response options yes or no. No to all responses = good adherence, while one or more Yes to responses = non-adherent. Non-adherence can be identified as mainly unintentional (factor 1) or purposeful (factor 2), or mixed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-stroke at 12 months</measure>
    <time_frame>12 months post stroke; data collected over 12 months</time_frame>
    <description>proportion of stroke patients who experience a new stroke within 12 months of previous stroke</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Stroke</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stroke (exposure)</intervention_name>
    <description>stroke case definition (exposure) listed in inclusion/exclusion criteria section</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample separated into fractions (RBC, buffy coat, plasma), serum, and whole blood will&#xD;
      be stored for future studies (not part of the ZanStroke study)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All adults who get admitted to hospital in Unguja (Zanzibar) due to stroke, or develop&#xD;
        stroke while admitted to hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  admitted with a clinical diagnosis of stroke, or developing stroke while in hospital&#xD;
             admitted for other cause (see below for stroke case definition)&#xD;
&#xD;
          -  age above 18 year&#xD;
&#xD;
          -  written consent form signed by patient, or authorized representative (spouse or&#xD;
             caretaker)&#xD;
&#xD;
          -  stroke onset &lt; 30 days when enrolled&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patient or authorized representative unable to understand the information given or&#xD;
             being interviewed.&#xD;
&#xD;
          -  CT scan not suspect of stroke despite clinical suspect&#xD;
&#xD;
        Stroke case definition:&#xD;
&#xD;
        All the following stroke categories listed below that have been submitted as the most&#xD;
        responsible diagnosis will be included in the stroke cohort. For patients developing stroke&#xD;
        while admitted to hospital, stroke as the second diagnosis will also be included in the&#xD;
        cohort. Patients who previously had a stroke and are being admitted due to complications,&#xD;
        and where stroke is not the primary diagnosis during admission, will not be included in the&#xD;
        cohort.&#xD;
&#xD;
        Definition of stroke ( ICD-10 classification code in parenthesis) that will be used in the&#xD;
        study for inclusion in the cohort:&#xD;
&#xD;
        (a) Intracerebral hemorrhage (I61 including all sub-codes) (b) Ischemic stroke (I63&#xD;
        including all sub-codes, H34.1) (c) Stroke, not specified as hemorrhagic or ischemic (I64)&#xD;
        (d) Cerebral Venous Thrombosis, non-pyogenic (I63.6) Where CTscan is not available, the&#xD;
        clinical diagnosis of stroke will be used, and coding will be I64 (ICD-10)&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jutta A Jorgensen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mnazi Mmoja Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kivunge District Hospital</name>
      <address>
        <city>Kinyasini</city>
        <state>Zanzibar</state>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mnazi Mmoja Hospital</name>
      <address>
        <city>Zanzibar</city>
        <zip>236</zip>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Al Rahma Hospital</name>
      <address>
        <city>Zanzibar</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bububu Military Hospital</name>
      <address>
        <city>Zanzibar</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KMKM hospital Bububu</name>
      <address>
        <city>Zanzibar</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Makunduchi District hospital</name>
      <address>
        <city>Zanzibar</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tasakthaa Global Hospital</name>
      <address>
        <city>Zanzibar</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tawakala hospital</name>
      <address>
        <city>Zanzibar</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tanzania</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>September 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2019</study_first_posted>
  <last_update_submitted>March 31, 2021</last_update_submitted>
  <last_update_submitted_qc>March 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mnazi Mmoja National Referral Hospital</investigator_affiliation>
    <investigator_full_name>Jutta Mari Adelin Jorgensen</investigator_full_name>
    <investigator_title>Principal Investigator of ZanStroke, Dr. Jutta Mari Adelin Jorgensen</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

